04:48 AM EDT, 07/13/2026 (MT Newswires) -- Ixico (IXI.L) said Monday that two Huntington's disease programs it was supporting were discontinued by their sponsors. The discontinuation will reduce 1.5 million pounds sterling from the neuroscience imaging and biomarker analytics company's contracted order book within the next two financial years.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.